Epidemiology and clinical relevance of Pneumocystis jirovecii Frenkel, 1976 dihydropteroate synthase gene mutations

Parasite

Volumn 17, Issue 3, 2010, Pages 219-232

  Matos, O ^a   Esteves, F ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Dihydropteroate synthase; Gene mutation; HIV; Pneumocystis jirovecii; Pneumonia; Sulpha; Sulphone

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS JIROVECII;

EID: 77956672260     PISSN: 1252607X     EISSN: None     Source Type: Journal    
DOI: 10.1051/parasite/2010173219     Document Type: Conference Paper

References (83)

1. ALVAREZ-MARTÍNEZ M. J., MORENO A., MIRÓJ.M., VALLS M.E., RIVAS P.V., DE LAZZARI E., SUED O., BENITO N., DOMINGO P., RIBERA E., SANTÍN M., SIRERA G., SEGURA F., VlDAL F., RODRÍGUEZ F., RIERA M., CORDERO M.E., ARRIBAS J.R., JIMÉNEZ DE ANTA M.T., GATELL J.M., WILSON P.E., MESHNICK S.R.; SPANISH PCP WORKING GROUP. Pneumocystis jirovecii pneumonia in Spanish HIVinfected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagnostic Microbiology and Infectious Diseases, 2008, 62(1), 34-43.
2. ARMSTRONG W., MESHNICK S. & KAZANJLAN P. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes and Infection, 2000, 2, 61-67.
3. BARRY S.M. & JOHNSON M.A. Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management. HIV Medicine, 2001, 2, 123-132.
4. BEARD C.B., CARTER J.L., KEELY S.P., HUANG L., PIENLAZEK N.J., MOURA I.N., ROBERTS J.M., HIGHTOWER A.W., BENS M.S., FREEMAN A.R., LEE S., STRINGER J.R., DUCHIN J.S., DEL RIO C., RIMLAND D., BAUGHMAN R.P., LEVY D.A., DIETZ V.J., SIMON P. & NAVIN T.R. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerging Infectious Diseases, 2000, 6, 265-272.
5. BENSON C.A., KAPLAN J.E., MASUR H., PAU A. & HOLMES K.K. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Diseases Society of America. MMWR Recommen-dations and Reports, 2004, 53, 1-112.
6. BONORA S., DI PERRI G., VENTO S., CAZZADORI A. & CONCLA E. Failure of prophylaxis against PCP in patients with HIV infec-tion. AIDS Patient Care and STDs, 1998, 12, 843-848.
7. BOZZETTE S.A., FINKELSTEIN D.M., SPECTOR S.A., FRAME P., POWDERLY W.G., HE W., PHILLIPS L., CRAVEN D., VAN DER HORST C. & FEINBERG J. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 1995, 332, 693-699.
8. BROOKS D.R., WANG P., READ M., WATKINS W.M., SIMS P.F. & HYDE J.E. Sequence variation of the hydroxymethyldihy-dropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. European Journal of Biochemistry, 1994, 224, 397-405.
9. BUSHBY S.R.M. Antibacterial activity, in: Inhibition of Folate Metabolism in Chemotherapy. Hitchings G.H. (ed.), Springer-Verlag, New York, 1983, 75-105.
10. CENTERS FOR DISEASE CONTROL. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. Morbidity and Mortality Weekly Report, 1992,41,1-11.
11. COSTA M.C., HELWEG-LARSEN J., LUNDGREN B., ANTUNES F. & MATOS O. Mutations in the dihydropteroate synthase gene of Pneumocystis jirovecii isolates from Portuguese patients with Pneumocystis pneumonia. International Journal of Antimicrobial Agents, 2003, 22 (5), 516-520.
12. CROTHERS K., BEARD C.B., TURNER J., GRONER G., Fox M., MORRIS A., EISER S. & HUANG L. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumo-cystis jirovecii dihydropteroate synthase gene mutations. AIDS, 2005, 19, 801-805.
13. DINI L., DU PLESSIS M., FREAN J. & FERNANDEZ V. High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneu-monia in South Africa. Journal of Clinical Microbiology, 2010, 48, 2016-2021.
14. ESTEVES F., GASPAR J., TAVARES A., MOSER I., ANTUNES F., MANSINHO K. & MATOS O. Population structure of Pneumocystis jirovecii isolated from immunodeficiency virus-positive patients. Infection Genetics and Evolution, 2010, 10, 192-199.
15. ESTEVES F., MONTES-CANO M.A., DE LA HORRA C., COSTA M.C., CALDERÓN E.J., ANTUNES F. & MATOS O. Pneumocystis jirovecii multilocus genotyping profiles in patients from Portugal and Spain. Clinical Microbiology and Infection, 2008, 14, 356-362.
16. FRENCH N., KALEEBU P., PISANI E. & WHITWORTH J.A.G. Human immunodeficiency virus (HIV) in developing countries. Annals of Tropical Medicine and Parasitology, 2006, 100, 433-454.
17. HAUSER P.M., SUDRE P., NAHIMANA A. & FRANCIOLI P., AND THE STUDY GROUP. Prophylaxis failure is associated with a specific Pneumocystis carinii Genotype. Clinical Infectious Diseases, 2001, 33, 1080-1082.
18. HELWEG-LARSEN J., BENFIELD T.L., EUGEN-OLSEN J., LUNDGREN J.D. & LUNDGREN B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase on outcome of AIDS-associated P. carinii pneumonia. Lancet, 1999, 354, /1347-1351.
19. HUANG L., BEARD C.B., CREASMAN J., LEVY D., DUCHIN J.S., LEE S., PIENIAZEK N., CARTER J.L., DEL RIO C, RIMLAND D. & NAVIN T.R. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. The Journal of Infectious Diseases, 2000, 182, 1192-1198.
20. HUANG L., CROTHERS K., ATZORI C, BENFIELD T., MILLER R., RABODONIRINA M., HELWEG-LARSEN J. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerging Infectious Diseases, 2004, 10, 1721-1728.
21. ILIADES P., WALKER D.J., CASTELLI L., SATCHELL J., MESHNIC S.R. & MACREADIE I.G. Cloning of the Pneumocystis jirovecii trifunctional FAS gene and complementation of its DHPS activity in Escherichia coli. Fungal Genetic and Biology, 2004, 41, 1053-1062.
22. KANEKO Y., SUWA A., IKEDA Y. & HIRAKATA M. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature. Rheumatology, 2006, 16, 36-38.
23. KAPLAN J.E., BENSON C., HOLMES K.H., BROOKS J.T., PAU A. & MASUR H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommendations and Reports, 2009, 58 (RR-4), 1-207, quiz CE1-4.
24. KAPLAN J.E., HANSON D., DWORKIN M.S., FREDERICK T., BERTOLLI J., LINDEGREN M.L., HOLMBERG S. & JONES J.L. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical Infectious Diseases, 2000,30 (Suppl. 1), S5-S14.
25. KAPLAN J.E., MASUR H.& HOLMES K.K. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recommendations and Reports, 2002, 51 (RR-8), 1-52.
26. KAZANJIAN P., ARMSTRONG W., HOSSLER P.A., BURMAN W., RICHARDSON J., LEE C.H., CRANE L., KATZ J. & MESHNICK S.R. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. The Journal of Infectious Diseases, 2000, 182, 551-557.
27. KAZANJIAN P., LOCKE A.B., HOSSLER P.A., LANE B.R., BARTLETT M.S., SMITH J.W., CANNON M. & MESHNICK S.R. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS, 1998, 12, 873-878.
28. KAZANJLANP.H., FISK D., ARMSTRONG W., SHULINQ., LIWEI H., KE Z. & MESHNICK S. Increase in Prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China. The Journal of Infectious Diseases, 2004, 189, 1684-1687.
29. KIMCHI-SARFATY C., OH J.M., KIM I.W., SAUNA Z.E., CALCAGNO A.M., AMBUDKAR S.V. & GOTTESMAN M.M. A "silent" polymorphism in the MDRl gene changes substrate specificity. Science, 2007, 315, 525-528.
30. KLEIN N.C., DUNCANSON F.P., LENO, T.H., FORSZPANIAK C, SHERER C.B., QUENTZEL H., NUNEZ M., SUAREZ M., KAWWAFF O., PITTAALVAREZ A. et al Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS, 1992, 6, 301-305.
31. KOVACS J.A., Allegra C.J., Beaver J, Boarman D., Lewis M., Parrillo J.E., Chabner B. & Masur H. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. The Journal of Infectious Diseases, 1989, 160, 312-320.
32. LANE B.R., AST J. C., HOSSLER P.A., MINDELL D.P., BARTLETT M.S., SMITH J.W. & MESHNICK S.R. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. The Journal of Infectious Diseases, 1997, 175, 482-485.
33. LATOUCHE S., LACUBE P., MAURY E., BOLOGNINI J., DEVELOUX M., GIRARD P.M., GODET C., LEBRETTE M.G., MAYAUD C., GUILLOT J. & Roux P. Pneumocystis jirovecii dihydropteroate synthase genotypes in French patients with pneumocystosis: a 1998-2001 prospective study. Medical Mycology, 2003, 41, 533-537.
34. Li K., HE A., CAI W.P., TANG X.P., ZHENG X.Y., LI Z.Y. & ZHAN X.M. Absence of Pneumocystis jirovecii dihydropteroate synthase gene mutations among samples from a group of AIDS patients in China. Scandinavian Journal of Infectious Diseases. 2009, 41, 152-154.
35. LOPEZ P., ESPINOSA M., GREENBERG B. & LACKS S.A. Sulfonamide resistance in Streptococcus pneumoniae: DNA sequence of the gene encoding dihydropteroate synthase and characterization of the enzyme. Journal of Bacteriology, 1987, 169, 4320-4326.
36. LUNDBERG B.E., Davidson A.J. & Burman W.J. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS, 2000, 14, 2559-2566.
37. MA L, KOVACS J.A., CARGNEL A., VALERIO A., FANTONI G. & ATZORI C Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis. The Journal of Infectious Diseases, 2002, 185, 1530-1532.
38. MA L., BORIO L., MASUR H. & KOVACS J.A. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprimsulfamethoxazole or dapsone use. The Journal of Infectious Diseȧses, 1999, 180, 1969-1978.
39. MARTIN J.N., ROSE D.A., HADLEY W.K., PERDREAU-REMINGTON F., LAM P.K. & GERBERDING J.L. Emergence of trimethoprimsulfamethoxazole resistance in the AIDS era. The Journal of Infectious Diseases, 1999, 180, 1809-1818.
40. MASUR H. Prevention and treatment of Pneumocystis pneumonia. New England Journal of Medicine, 1992, 327, 1853-1860.
41. MATOS O., COSTA M.C., CORREIA I., MONTEIRO P., VIEIRA J.R., SOARES J., BONNET M., ESTEVES F. & ANTUNES F. Pneumocystis jiroveci infection in immunocompetent patients with pulmonary disorders, in Portugal. Acta Médica Portuguesa, 2006, 19, 121-126.
42. MATOS O., COSTA M.C., CORREIA I., MONTEIRO. P., MONTEIRO M., SOARES J., VIEIRA J.R., BONNET M. & ANTUNES F. Pneumocystis jirovecii carriage in Portuguese immunocompetent patients: preliminary results. Journal of Eukaryotic Microbiology, 2003, 50 (Suppl.), 647-648.
43. MEDRANO F.J., MONTES-CANO M., CONDE M., DE LA HORRA C., RESPALDIZA N., GASCH A., PEREZ-LOZANO M.J., VARELA J.M. & CALDERON E.J. Pneumocystis jirovecii in general population. Emerging Infectious Diseases, 2005, 11, 245-250.
44. MEI Q., GURUNATHAN S., MASUR H. & KOVACS J.A. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet, 1998,351, 1631-1632.
45. rd ed. Walzer P. & Cushion M.T. (eds), Marcel Dekker, New York, 2005, 631-640.
46. MILLER R.F., LINDLEY A.R., AMBROSE H.E., MALIN A.S., WAKEFIELD A.E. Genotypes of Pneumocystis jirovecii isolates obtained in Harare, Zimbabwe, and London, United Kingdom. Antimicrobial Agents and Chemotherapy, 2003, 47, 3979-3981.
47. MONTES-CANO M.A, DE LA HORRA C., MARTIN-JUAN J., VARELA J.M., TORRONTERAS R., RESPALDIZA N., MEDRANO F.J., & CALDERÓN E.J. Pneumocystis jiroveci genotypes in the Spanish population. Clinical Infectious Diseases, 2004,39, 123-128.
48. MOORMAN A.C., VON BARGEN J.C., PALELLA F.J.& HOLMBERG S.D. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) investigators. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998, 19, 182-188.
49. MORRIS A., LUNDGREN J.D., MASUR H., WALZER P.D., HANSON D.L., FREDERICK T., HUANG L., BEARD C.B. & KAPLAN J.E. Current epidemiology of Pneumocystis pneumonia. Emerging Infectious Diseases, 2004, 10, 1713-1720.
50. NAHIMANA A., RABODONIRINA M., HELWEG-LARSEN J., MENEAU I., FRANCIOLI P., BILLE J. & HAUSER P.M. Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia. Emerging Infectious Diseases, 2003, 9, 864-867.
51. NAVIN T.R., BEARD C.B., HUANG L., DEL RIO C., LEE S., PIENIAZEK N.J., CARTER J.L., LE T., HIGHTOWER A. & RIMLAND D. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet, 2001, 358, 545-549.
52. PALELLA F.J. JR., DELANEY K.M., MOORMAN A.C., LOVELESS M.O., FUHRER J., SATTEN G.A., ASCHMAN D.J.& HOLMBERG S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New England Journal of Medicine, 1998, 338, 853-860.
53. PIFER L.L., HUGHES W.T., STAGNO S. & WOODS D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics, 1978,61,35-41.
54. POPPERS D.M. & SCHERL EJ. Prophylaxis against Pneumo-cystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflammatory Bowel Diseases, 2008, 14 (1), 106-113.
55. REDHEAD S.A., CUSHION M.T., FRENKEL J.K. & STRINGER J.R. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. Journal ofEukaryotic Microbiology, 2006,53,2-11.
56. RIEBOLD D. & REISINGER E.C Pneumocystis jiroveci partial DHPS gene for dihydropteroate synthase, isolate 171. NCBI accession number AJ586567, 16.10.2003.
57. RIEBOLD D., FRITZSCHE C., LADEMANN M., BIER A. & REISINGER E.C. Pneumocystis jiroveci dihydropteroate synthase gene mutations at codon 171 but not at codons 55 or 57 detected in Germany. Clinical Infectious Diseases, 2006, 42, 582-583.
58. RIEBOLD D., MUNK A.K. & REISINGER E.C. Pneumocystis jiroveci partial mRNA for dihydropteroate synthase. NCBI accession number AJ746341, 07.06.2004.
59. ROBBERTS F.J.L., CHALKLEY L.J., WEYER K., GOUSSARD P. & LIEBOWITZ L.D. Dihydropteroate synthase and novel dihydrofolate reductase gene mutations in strains of Pneumocystis jirovecii from South Africa. Journal of Clinical Microbiology, 2005, 43, 1443-1444.
60. SANTOS L.D., LACUBE P., LATOUCHE S., KAC G., MAYAUD C., MARTEAU M., POIROT J.L., MAURY E., GUILLOT J. & Roux P. Contribution of dihydropteroate synthase gene typing for Pneumocystis carinii f. sp. hominis epidemiology. Journal of Eukaryotic Microbiology, 1999, 46, 133S-134S.
61. SEPKOWITZ K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clinical Infectious Diseases, 2002, 34, 1098-1107
62. [Erratum, Clin Infect Dis 2002, 34, 1293].
63. SHEN L.X., BASILION J.P. & STANTON V.P. Jr. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7871-7876.
64. SIRIPATTANAPIPONG S., LEELAYOOVA S., MUNGTHIN M., WORAPONG J. & TAN-ARIYA P. Study of DHPS and DHFR genes of Pneumocystis jirovecii in Thai HIV-infected patients. Medical Mycolology, 2008, 46, 389-392.
65. STRINGER J.R., BEARD C.B., MILLER R.F. & WAKEFIELD A.E. A new name (Pneumocystis jirovecii) for Pneumocystis from humans. Emerging Infectious Diseases, 2002, 8, 891-896.
66. TAKAHASHI T., HOSOYA N., ENDO T., NAKAMURA T., SAKASHITA H., KIMURA K., OHNISHI K., NAKAMURA Y. & IWAMOTO A. Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. Journal of Clinical Microbiology, 2000, 38, 3161-3164.
67. TOTET A., LATOUCHE S., LACUBE P., PAUTARD J.C., JOUNIEAUX V., RACCURT C., ROUX P. & NEVEZ G. Pneumocystis jirovecii dihydropteroate synthase genotypes in immunocompetent infants and immunosuppressed adults, Amiens, France. Emerging Infectious Diseases, 2004, 10, 667-673.
68. TRIGLIA T., WANG P., SIMS P.F., HYDE J.E. & COWMAN A.F. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. The Embo Journal, 1998, 17, 3807-3815.
69. TYAGI A.K., MIRDHA B.R., GULERIA R., MOHAN A., LUTHRA K. & SINGH U.B. Study of dihydropteroate synthase (DHPS) gene mutations among isolates of Pneumocystis jiroveci. Indian Journal of Medical Research. 2008, 128, 734-739.
70. VALERIO A., TRONCONI E., MAZZA F., FANTONI G., ATZORI C., TARTARONE F., DUCA P. & CARGNEL A. Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. Journal of Acquired Immune Deficiency Syndrome, 2007, 45, 521-528.
71. VAN HAL S.J., GILGADO F., DOYLE T., BARRATT J., STARK D., MEYER W. & HARKNESS J. Clinical significance and phylogenetic relationship of novel Australian Pneumocystis jirovecii genotypes. Journal of Clinical Microbiology, 2009, 47, 1818-1823.
72. VEDANTAM G., GUAY G.G., AUSTRIA N.E., DOKTOR S.Z. & NICHOLS B.P. Characterization of mutations contributing to sulfathiazole resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy, 1998, 42, 88-93.
73. VIDAL S., DE LA HORRA C., MARTÍN J., MONTES-CANO M.A., RODRÍGUEZ E., RESPALDIZA N., RODRÍGUEZ F., VARELA J.M., MEDRANO F.J. & CALDERÓN E.J. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clinical Microbiology and Infection, 2006, 12, 231-235.
74. VISCONTI E., ORTONA E., MENCARINI P., MARGUTTI P., MARINACI S., ZOLFO M., SIRACUSANO A. & TAMBURRINI E. Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia. International Journal of Antimicrobial Agents, 2001, 18, 547-551.
75. VOLPE F., DYER M., SCAIFE J.G., DARBY G., STAMMERS D.K. & DELVES C.J. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii appears to encode dihydropteroate synthase and hydroxymethyldihydropterin pyrophosphokinase. Gene, 1992, 112, 213-218.
76. WAKEFIELD A.E. Pneumocystis carinii. British Medical Bulletin, 2002, 61, 175-188.
77. WALZER P.D., FOY J., STEELE P., KIM C.K., WHITE M., KLEIN R.S., OTTER B.A. & ALLEGRA C. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy, 1992, 36, 1935-1942.
78. WISSMANN G., ALVAREZ-MARTINEZ M.J., MESNHICK S.R., DIEHL A.R., PROLLA J.C. Absence of dihydropteroate synthase mutations in Pneumocystis jirovecii from Brazilian AIDS patients. Journal of Eukaryotic Microbiology, 2006, 53, 305-307.
79. WOLFF A.J. & O'DONNELL A.E. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest, 2001, 120, 1888-1893.
80. WORMSER G.P. & KEUSCH G.T. Trimethoprim-sulfamethoxazole in the United States. Annals of Internal Medicine, 1979,91, 420-429.
81. WORLD HEALTH ORGANISATION. World Health Organization treating 3 million by 2005: making it happen: the WHO strategy: the WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005/Treat 3 million by 2005. http://libdoc.who.int/publications/2003/9241591129.pdf. [Accessed 20 January 2010].
82. ZAR H.J., ALVAREZ-MARTINEZ M.J., HARRISON A. & MESHNICK S.R. Prevalence of dihydropteroate synthase mutants in HIVinfected South African children with Pneumocystis jiroveci pneumonia. Clinical Infectious Diseases, 2004, 39, 1047-1051.
83. ZINGALE A., CARRERA P., LAZZARIN A., SCARPELLINI P. Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. Journal of Clinical Microbiology, 2003, 41, 2709-2712.